Additionally, as DOACs are now ubiquitous in the context of VTE primary treatment, there is a continued need to evaluate their comparative effectiveness in the context of VTE, and to understand how to optimize their management in high\risk situations. RELATIONSHIP DISCLOSURE The authors report nothing to disclose. AUTHOR CONTRIBUTIONS PLL, AA, and NZ conceived the study; PLL, RWF, and RFM conducted the data analysis; all authors provided critical intellectual input on the manuscript draft. Supporting information ? Click here for additional data file.(89K, doc) ACKNOWLEDGMENTS This work was supported by NIH National Heart Lung and Blood Institute grants R01\HL131579 and R01\HL122200. Notes Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. of 2017, warfarin was prescribed to 17.5%, while rivaroxaban was prescribed to 42.7%, apixaban to 38.6%, dabigatran to 1 1.3%, and edoxaban to 0.1%. In 2017, the comorbidity burden was highest among patients prescribed warfarin, intermediate among patients prescribed apixaban, and lowest among patients prescribed rivaroxaban. Conclusions Rivaroxaban and apixaban use to treat VTE has increased dramatically since receiving FDA approval, whereas warfarin use has plummeted. Dabigatran and edoxaban are infrequently prescribed. Given widespread usage of rivaroxaban and apixaban, there is a need for continued monitoring of the comparative effectiveness of these OAC therapies in real\world settings. values for differences in patient characteristics between OACs were calculated using tests for continuous variables and chi\square tests for dichotomous variables. 3.?RESULTS AND DISCUSSION Our sample included 137?203 VTE patients who were on average (standard deviation [SD]) 56.7 16.3?years old and 49.9% female. Warfarin was prescribed to 98.7% of anticoagulant\na?ve VTE patients receiving an OAC in quarter 1 of 2012 (Figure?2). By quarter 4 of 2017, use of warfarin had decreased dramatically, being prescribed to only 17.5% of VTE patients. Rivaroxaban was prescribed to 42.7%, apixaban to 38.6%, dabigatran to 1 1.3% and edoxaban to 0.1%. Use of rivaroxaban has been somewhat stable since 2014 quarter 2 when it was prescribed to 40.8%. Apixaban has continued to gain market share in virtually every quarter since its FDA approval in 2014 quarter 3. It is unclear whether this pattern will continue or if it, too, will stabilize. How a physician and patient decide between rivaroxaban and apixaban is also not clear. Both have a similar mechanism of action (factor Xa inhibitors),13 but rivaroxaban is a once\daily regimen, whereas apixaban is twice daily. In comparative effectiveness studies, we9 and others14 have recently shown that risk of major bleeding is lower among users of apixaban than users of rivaroxaban. The extremely low use of dabigatran and edoxaban may be explained, at least partially, by their need for initial parenteral anticoagulation or differences in Rabbit Polyclonal to MARCH3 reimbursement relative to other OAC options. Results were similar when we restricted our analysis to participants with no evidence of atrial fibrillation (data not shown). Similar to our findings, an analysis of the Danish Nationwide Cohort study showed dramatic shifts in OAC use between February 2012 and September 2016.15 By September 2016, 12% of Danish VTE patients were initially prescribed warfarin, 70% rivaroxaban, 16% apixaban, and 2% dabigatran. Open in a separate window Figure 2 Temporal trends in oral anticoagulants prescribed for the primary treatment of venous thromboembolism from 2012 through 2017 Among patients initiating OAC therapy for VTE primary treatment in 2017, those prescribed warfarin were on average (SD) 57.2??16.4?years old and had the most comorbidities. Patients prescribed apixaban were similar in age to patients prescribed warfarin (56.8??15.9) but had a slightly lower comorbidity burden, while patients prescribed rivaroxaban were the youngest (53.4??14.8?years) and had the fewest comorbidities (Table?1). Keeping in mind that in 2017 (quarters 1\4) 19.3% of patients were prescribed warfarin, 42.5% rivaroxaban, and 36.8% apixaban, these findings indicate that there is widespread usage of apixaban and rivaroxaban across patients with an array MI-136 of comorbidities. Table 1 Characteristics of venous thromboembolism patients by anticoagulant initially prescribed, MarketScan databases, 2017 value /th th align=”left” valign=”top” rowspan=”1″ colspan=”1″ Rivaroxaban vs. warfarin /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Apixaban vs. warfarin /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Apixaban vs. rivaroxaban /th /thead Age, y57.2??16.453.4??14.856.8??15.9 0.000.42 0.00Female, %49.949.750.50.890.630.43Comorbidities, %Hypertension60.547.459.1 0.000.29 0.00Diabetes mellitus24.316.922.1 0.000.05 0.00Myocardial infarction9.64.36.5 0.00 0.00 0.00Heart failure18.17.913.4 0.00 0.00 0.00Atrial fibrillation9.34.68.9 0.000.61 0.00Ischemic stroke3.92.03.3 0.000.28 0.00Peripheral artery disease15.38.012.7 0.000.004 0.00Dementia4.11.63.2 0.000.08 0.00Chronic pulmonary disease23.219.822.10.0010.360.007Renal disease15.15.310.4 0.00 0.00 0.00Liver disease8.66.48.00.0010.360.01Depression20.216.017.7 0.000.020.03Hematologic disorders15.28.710.2 0.00 0.000.02Alcohol misuse3.02.42.60.160.480.41Medications, %Antiplatelets6.53.25.5 0.000.10 0.00ACE inhibitors21.116.721.4 0.000.81 0.00Angiotensin receptor blockers14.312.115.00.010.47 0.0001Beta\blockers27.317.925.2 0.000.08 0.00Calcium channel blockers18.113.618.6 0.000.59 0.00Statins30.023.729.3 0.000.60 0.00Diabetes mellitus medications6.33.84.8 0.000.020.01SSRIs27.124.226.00.010.360.05 Open in a separate window ACE, angiotensin\converting enzyme; SSRI, selective serotonin reuptake inhibitors. Ideals correspond to mean??standard deviation or percentage. Advantages of this study are the large sample of US covered individuals, info on comorbidities, and availability of data since the authorization of DOACs for VTE main treatment. Limitations are potential misclassification in the exposure status (because the validity of DOACs in administrative data have not been identified) and in the recognition of individuals with event VTE and various comorbidities. However, founded algorithms were used.10, 12 We also lack information about what led to selection.N Engl J Med. to 42.7%, apixaban to 38.6%, dabigatran to 1 1.3%, and edoxaban to 0.1%. In 2017, the comorbidity burden was highest among individuals prescribed warfarin, intermediate among individuals prescribed apixaban, and least expensive among patients prescribed rivaroxaban. Conclusions Rivaroxaban and apixaban use to treat VTE has improved dramatically since receiving FDA authorization, whereas warfarin use offers plummeted. Dabigatran and edoxaban are infrequently prescribed. Given widespread usage of rivaroxaban and apixaban, there is a need for continuing monitoring of the comparative performance of these OAC therapies in actual\world settings. ideals for variations in patient characteristics between OACs were calculated using checks for continuous variables and chi\square checks for dichotomous variables. 3.?RESULTS AND Conversation Our sample included 137?203 VTE individuals who were normally (standard deviation [SD]) 56.7 16.3?years old and 49.9% female. Warfarin was prescribed to 98.7% of anticoagulant\na?ve VTE patients receiving an OAC in quarter 1 of 2012 (Number?2). By quarter 4 of 2017, use of warfarin experienced decreased dramatically, being prescribed to only 17.5% of VTE patients. Rivaroxaban was prescribed to 42.7%, apixaban to 38.6%, dabigatran to 1 1.3% and edoxaban to 0.1%. Use of rivaroxaban has been somewhat stable since 2014 quarter 2 when it was prescribed to 40.8%. Apixaban offers continued to gain market share in virtually every quarter since its FDA authorization in 2014 quarter 3. It is unclear whether this pattern will continue or if it, too, will stabilize. How a physician and patient decide between rivaroxaban and apixaban is also not clear. Both have a similar mechanism of action (element Xa inhibitors),13 but rivaroxaban is definitely a once\daily routine, whereas apixaban is definitely twice daily. In comparative performance studies, we9 and others14 have recently demonstrated that risk of major bleeding is lower among users of apixaban than users of rivaroxaban. The extremely low use of dabigatran and edoxaban may be explained, at least partially, by their need for initial parenteral anticoagulation or variations in reimbursement relative to other OAC options. Results were related when we restricted our analysis to participants with no evidence of atrial fibrillation (data not shown). Similar to our findings, an analysis of the Danish Nationwide Cohort study showed dramatic shifts in OAC use between February 2012 and September 2016.15 By September 2016, 12% of Danish VTE individuals were initially prescribed warfarin, 70% rivaroxaban, 16% apixaban, and 2% dabigatran. Open in a separate window Number 2 Temporal styles in oral anticoagulants prescribed for the primary treatment of venous thromboembolism from 2012 through 2017 Among individuals initiating OAC therapy for VTE main treatment in 2017, those prescribed warfarin were normally (SD) 57.2??16.4?years old and had probably the most comorbidities. Individuals prescribed apixaban were similar in age to patients prescribed warfarin (56.8??15.9) but had a slightly reduce comorbidity burden, while individuals prescribed rivaroxaban were the youngest (53.4??14.8?years) and had the fewest comorbidities (Table?1). Keeping in mind that in 2017 (quarters 1\4) 19.3% of individuals were prescribed warfarin, 42.5% rivaroxaban, and 36.8% apixaban, these findings indicate that there is widespread usage of apixaban and rivaroxaban across individuals with an array of comorbidities. Table 1 Characteristics of venous thromboembolism individuals by anticoagulant in the beginning prescribed, MarketScan databases, 2017 value /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Rivaroxaban vs. warfarin /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Apixaban vs. warfarin /th th align=”remaining” valign=”top” rowspan=”1″ colspan=”1″ Apixaban vs. rivaroxaban /th /thead Age, y57.2??16.453.4??14.856.8??15.9 0.000.42 0.00Female, %49.949.750.50.890.630.43Comorbidities, %Hypertension60.547.459.1 0.000.29 0.00Diabetes mellitus24.316.922.1 0.000.05 0.00Myocardial infarction9.64.36.5 0.00 0.00 0.00Heart failure18.17.913.4 0.00 0.00 0.00Atrial fibrillation9.34.68.9 0.000.61 0.00Ischemic stroke3.92.03.3 0.000.28 0.00Peripheral artery disease15.38.012.7 0.000.004 0.00Dementia4.11.63.2 0.000.08 0.00Chronic pulmonary disease23.219.822.10.0010.360.007Renal disease15.15.310.4 0.00 0.00 0.00Liver disease8.66.48.00.0010.360.01Depression20.216.017.7 0.000.020.03Hematologic disorders15.28.710.2 0.00 0.000.02Alcohol misuse3.02.42.60.160.480.41Medications, %Antiplatelets6.53.25.5 0.000.10 0.00ACE inhibitors21.116.721.4 0.000.81 0.00Angiotensin receptor blockers14.312.115.00.010.47 0.0001Beta\blockers27.317.925.2 0.000.08 0.00Calcium channel blockers18.113.618.6 0.000.59 0.00Statins30.023.729.3 0.000.60 0.00Diabetes mellitus medications6.33.84.8 0.000.020.01SSRIs27.124.226.00.010.360.05 Open in a separate window ACE, angiotensin\converting enzyme; SSRI, selective serotonin reuptake inhibitors. Ideals correspond to mean??standard deviation or percentage. Advantages of this study are the large sample of US insured individuals, info on comorbidities, and availability of data since the authorization of DOACs for VTE main treatment. Limitations are potential misclassification in the exposure status (because the validity of DOACs in administrative data have not been identified) and in the recognition of individuals with event VTE and various comorbidities. However, founded algorithms were used.10, 12 We lack information about what led to selection of a also.Direct dental anticoagulants and warfarin for venous thromboembolism treatment: Tendencies from 2012 to 2017. VTE sufferers getting an OAC in one fourth 1 (January through March) of 2012. By one fourth 4 (Oct through Dec) of 2017, warfarin was recommended to 17.5%, while rivaroxaban was recommended to 42.7%, apixaban to 38.6%, dabigatran to at least one 1.3%, and edoxaban to 0.1%. In 2017, the comorbidity burden was highest among sufferers recommended warfarin, intermediate among sufferers recommended apixaban, and minimum among patients recommended rivaroxaban. Conclusions Rivaroxaban and apixaban make use of to take care of VTE has elevated significantly since getting FDA acceptance, whereas warfarin make use of provides plummeted. Dabigatran and edoxaban are infrequently recommended. Given widespread using rivaroxaban and apixaban, there’s a need for ongoing monitoring from the comparative efficiency of the OAC therapies in true\world settings. beliefs for distinctions in patient features between OACs had been calculated using exams for continuous factors and chi\square exams for dichotomous factors. 3.?Outcomes AND Debate Our test included 137?203 VTE sufferers who were typically (regular deviation [SD]) 56.7 16.3?years of age and 49.9% female. Warfarin was recommended to 98.7% of anticoagulant\na?ve VTE individuals receiving an OAC in one fourth 1 of 2012 (Body?2). By one fourth 4 of 2017, usage of warfarin acquired decreased significantly, being recommended to just 17.5% of VTE patients. Rivaroxaban was recommended to 42.7%, apixaban to 38.6%, dabigatran to at least one 1.3% and edoxaban to 0.1%. Usage of rivaroxaban continues to be somewhat steady since 2014 one fourth 2 when MI-136 it had been recommended to 40.8%. Apixaban provides continued to get market talk about in just about any one fourth since its FDA acceptance in 2014 one fourth 3. It really is unclear whether this design will continue or if it, as well, will stabilize. What sort of physician and individual decide between rivaroxaban and apixaban can be not yet determined. Both have an identical mechanism of actions (aspect Xa MI-136 inhibitors),13 but rivaroxaban is certainly a once\daily program, whereas apixaban is certainly double daily. In comparative efficiency research, we9 and others14 possess recently proven that threat of main bleeding is leaner among users of apixaban than users of rivaroxaban. The incredibly low usage of dabigatran and edoxaban could be described, at least partly, by their dependence on preliminary parenteral anticoagulation or distinctions in reimbursement in accordance with other OAC choices. Results were equivalent when we limited our evaluation to participants without proof atrial fibrillation (data not really shown). Similar to your findings, an evaluation from the Danish Nationwide Cohort research demonstrated dramatic shifts in OAC make use of between Feb 2012 and Sept 2016.15 By Sept 2016, 12% of Danish VTE sufferers were initially prescribed warfarin, 70% rivaroxaban, 16% apixaban, and 2% dabigatran. Open up in another window Body 2 Temporal tendencies in dental anticoagulants recommended for the principal treatment of venous thromboembolism from 2012 through 2017 Among sufferers initiating OAC therapy for VTE principal treatment in 2017, those recommended warfarin were typically (SD) 57.2??16.4?years of age and had one of the most comorbidities. Sufferers prescribed apixaban had been similar in age group to patients recommended warfarin (56.8??15.9) but had a slightly decrease comorbidity burden, while sufferers prescribed rivaroxaban were the youngest (53.4??14.8?years) and had the fewest comorbidities (Desk?1). Remember that in 2017 (quarters 1\4) 19.3% of sufferers were prescribed warfarin, 42.5% rivaroxaban, and 36.8% apixaban, these findings indicate that there surely is widespread using apixaban and rivaroxaban across sufferers with a range of comorbidities. Desk 1 Features of venous thromboembolism sufferers by anticoagulant originally prescribed, MarketScan directories, 2017 worth /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Rivaroxaban vs. warfarin /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Apixaban vs. warfarin /th th align=”still left” valign=”best” rowspan=”1″ colspan=”1″ Apixaban vs. rivaroxaban /th /thead Age group,.